Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.40 |
| ▸ | CCR2 | P41597 | 6/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478041 | 0.95 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2896864 | 0.92 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12012819 | 0.90 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL477933 | 0.90 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL478089 | 0.88 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL478285 | 0.87 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL478093 | 0.86 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2897136 | 0.86 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL478111 | 0.86 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL478120 | 0.85 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.